Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Capital Expenditures (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Capital Expenditures for 6 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 591.12% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, up 517.25% year-over-year, with the annual reading at $3.2 million for FY2025, 517.25% up from the prior year.
  • Capital Expenditures hit $1.5 million in Q4 2025 for Insight Molecular Diagnostics, up from $1.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q1 2022 to a low of -$564000.0 in Q3 2023.
  • Historically, Capital Expenditures has averaged $554888.9 across 5 years, with a median of $397500.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: soared 1813.64% in 2021 and later crashed 165.66% in 2023.
  • Year by year, Capital Expenditures stood at $401000.0 in 2021, then surged by 100.0% to $802000.0 in 2022, then plummeted by 67.08% to $264000.0 in 2023, then fell by 18.94% to $214000.0 in 2024, then skyrocketed by 591.12% to $1.5 million in 2025.
  • Business Quant data shows Capital Expenditures for IMDX at $1.5 million in Q4 2025, $1.0 million in Q3 2025, and $349000.0 in Q2 2025.